HealthyPlace.com Addictions Community

Addictions chat, forums, news, info

Sites

Alcoholism Recovery
The Art of Healing
Big Book
Center for On-Line
Addiction

Raw Psychology

The Stanton Peele
Addiction Website
Depression
and Addictions

Events

Healthyplace Radio
Support Groups

Information

Mental Health Videos
Bookstore
Columns
Conf. Transcripts
Diaries/Journals
Disorder Definitions
Medications
Online Tests
Resources

Support Lists

Email
ICQ
Instant Messenger

Community Wall

Visit & Post

Related
Communities

Abuse
Bipolar
Depression
Parenting
Personality Disorders
Relationships
send this page
to a friend


advertisement

 

advertisement

Alkermes Says Oral Alcohol Treatment Tests Well

(July 12, 2007) -- Alkermes Inc. said Monday new results from a clinical trial of ALKS 29, an oral treatment for alcohol dependence, are positive. Cambridge, Mass.-based Alkermes said ALKS 29 was generally well tolerated among alcohol-dependent patients tested and led to both a statistically significant increase in the percent of days abstinent and a decrease in drinking compared to placebo when combined with psychosocial therapy.

Based on these results, the company said it plans to move forward with its development program for oral product candidates to treat alcohol dependence.

Last year, Alkermes received approval from the U.S. Food and Drug Administration for Vivitrol, known generically as naltrexone. Vivitrol is a once-monthly injectable medication for the treatment of alcohol dependence and was developed with Cephalon Inc. of Frazer, Pa. 

Alkermes also has a schizophrenia treatment called Risperdal Consta on the market.

Source: Boston Business Journal

Last updated: 07/07

Related information:

back to top | more addiction news

 

advertisement

 

 

{short description of image}

Home to HealthyPlace.com

Chat Forums Communities Healthyplace Radio Support Groups
News
Bookstore Site Events Web Tour
Advertise Email Us

Search HealthyPlace.com

© 2000 HealthyPlace.com, Inc. All rights reserved. Terms of Use Privacy Policy Disclaimer